Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRYZ | Q08257 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693404 | 0.79 | CRYZ (1.00) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL6692264 | 0.77 | CRYZ (0.60) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL6695627 | 0.68 | CRYZ (0.61) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL20401809 | 0.68 | LMNA (0.53) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL6693338 | 0.67 | CRYZ (0.64) | CRYZMAPT | |
| SCHEMBL25230818 | 0.66 | LMNA (0.44) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL29116544 | 0.66 | LMNA (0.44) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL2756371 | 0.65 | LMNA (0.47) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL11631660 | 0.65 | SLC6A3 (0.47) | CRYZALDH1A1POLBLMNAGAA | |
| SCHEMBL173742 | 0.64 | ALDH1A1 (0.47) | CRYZALDH1A1POLBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | HU, LONGQIN | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214798-A1 | Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation | MKI67, NME2, NTPCR | CRYZ 1190/4885ALDH1A1 2164/4885POLB 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.